157 related articles for article (PubMed ID: 23430525)
1. Fabry disease in latin america: data from the fabry registry.
Villalobos J; Politei JM; Martins AM; Cabrera G; Amartino H; Lemay R; Ospina S; Ordoñez SS; Varas C
JIMD Rep; 2013; 8():91-9. PubMed ID: 23430525
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.
Politei JM; Cabrera G; Amartino H; Valdez R; Masllorens F; Ripeau D; Antongiovanni N; Soliani A; Luna P; Cedrolla M; Fernandez S; Fainboim A
Int J Clin Pract; 2013 Jan; 67(1):66-72. PubMed ID: 23241050
[TBL] [Abstract][Full Text] [Related]
3. The clinical profiles of female patients with Fabry disease in Latin America: A Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status.
Martins AM; Cabrera G; Molt F; Suárez-Obando F; Valdés RA; Varas C; Yang M; Politei JM
JIMD Rep; 2019 Sep; 49(1):107-117. PubMed ID: 31497488
[TBL] [Abstract][Full Text] [Related]
4. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
5. Demographic characterization of Brazilian patients enrolled in the Fabry Registry.
Martins AM; Kyosen SO; Garrote J; Marques FM; Guilhem JG; Macedo E; Sobral Neto J; Ura S
Genet Mol Res; 2013 Jan; 12(1):136-42. PubMed ID: 23408399
[TBL] [Abstract][Full Text] [Related]
6. Utility of rare disease registries in latin america.
Martins AM; Kerstenezky M; Linares A; Politei J; Kohan R; Ospina S; Varas C; Villalobos J; Amartino H; Franco S; Valadez G; Giugliani R; Guerra P; Sanches L
JIMD Rep; 2011; 1():111-5. PubMed ID: 23430837
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
8. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
[TBL] [Abstract][Full Text] [Related]
9. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.
Wanner C; Oliveira JP; Ortiz A; Mauer M; Germain DP; Linthorst GE; Serra AL; Maródi L; Mignani R; Cianciaruso B; Vujkovac B; Lemay R; Beitner-Johnson D; Waldek S; Warnock DG
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2220-8. PubMed ID: 20813854
[TBL] [Abstract][Full Text] [Related]
10. Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR
Anzueto A; Calverley PMA; Mueller A; Metzdorf N; Haensel M; Jardim JR; Pizzichini E; Giraldo H; Ramirez-Venegas A; Giugno ER
Arch Bronconeumol (Engl Ed); 2018 Mar; 54(3):140-148. PubMed ID: 29317111
[TBL] [Abstract][Full Text] [Related]
11. [Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher Disease].
Drelichman G; Linares A; Villalobos J; Cabello JF; Kerstenetzky M; Kohan RM; Martins AM
Medicina (B Aires); 2012; 72(4):273-82. PubMed ID: 22892077
[TBL] [Abstract][Full Text] [Related]
12. Multicity study of air pollution and mortality in Latin America (the ESCALA study).
Romieu I; Gouveia N; Cifuentes LA; de Leon AP; Junger W; Vera J; Strappa V; Hurtado-Díaz M; Miranda-Soberanis V; Rojas-Bracho L; Carbajal-Arroyo L; Tzintzun-Cervantes G;
Res Rep Health Eff Inst; 2012 Oct; (171):5-86. PubMed ID: 23311234
[TBL] [Abstract][Full Text] [Related]
13. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
Ripeau D; Amartino H; Cedrolla M; Urtiaga L; Urdaneta B; Cano M; Valdez R; Antongiovanni N; Masllorens F
Medicina (B Aires); 2017; 77(3):173-179. PubMed ID: 28643672
[TBL] [Abstract][Full Text] [Related]
14. Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).
Cunha-Borges JL; Mier GM; Casas N; Medina A; Molina JF; García ML; Oliveria LG; Caselato MS; Cruz AC; Ippolito V; Flórez S
Adv Rheumatol; 2019 Nov; 59(1):46. PubMed ID: 31703737
[TBL] [Abstract][Full Text] [Related]
15. Clinical manifestations and treatment of mucopolysaccharidosis type I patients in Latin America as compared with the rest of the world.
Muñoz-Rojas MV; Bay L; Sanchez L; van Kuijck M; Ospina S; Cabello JF; Martins AM
J Inherit Metab Dis; 2011 Oct; 34(5):1029-37. PubMed ID: 21541721
[TBL] [Abstract][Full Text] [Related]
16. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.
Sims K; Politei J; Banikazemi M; Lee P
Stroke; 2009 Mar; 40(3):788-94. PubMed ID: 19150871
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF.
Blumer V; Rivera M; Corbalán R; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Hellkamp AS; Singer DE; Fox KAA; Patel MR
Am Heart J; 2021 Jun; 236():4-12. PubMed ID: 33571477
[TBL] [Abstract][Full Text] [Related]
18. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.
Ortiz A; Abiose A; Bichet DG; Cabrera G; Charrow J; Germain DP; Hopkin RJ; Jovanovic A; Linhart A; Maruti SS; Mauer M; Oliveira JP; Patel MR; Politei J; Waldek S; Wanner C; Yoo HW; Warnock DG
J Med Genet; 2016 Jul; 53(7):495-502. PubMed ID: 26993266
[TBL] [Abstract][Full Text] [Related]
19. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey.
Hughes DA; Barba Romero MÁ; Hollak CE; Giugliani R; Deegan PB
Mol Genet Metab; 2011 Jul; 103(3):207-14. PubMed ID: 21543245
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.
Beck M; Hughes D; Kampmann C; Larroque S; Mehta A; Pintos-Morell G; Ramaswami U; West M; Wijatyk A; Giugliani R;
Mol Genet Metab Rep; 2015 Jun; 3():21-7. PubMed ID: 26937390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
